Fluproquazone (trade name Tormosyl, RF 46-790 ) was a quinazolinone derivative with potent analgesic, antipyretic, and anti-inflammatory effects discovered by Sandoz.[1][2][3][4] It was withdrawn during development due to liver toxicity.[5]: 370 [6]: 520 

Fluproquazone
Clinical data
ATC code
  • none
Identifiers
  • 4-(4-fluorophenyl)-7-methyl-1-propan-2-ylquinazolin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H17FN2O
Molar mass296.345 g·mol−1
3D model (JSmol)
  • Fc3ccc(C/1=N/C(=O)N(c2cc(ccc\12)C)C(C)C)cc3
  • InChI=1S/C18H17FN2O/c1-11(2)21-16-10-12(3)4-9-15(16)17(20-18(21)22)13-5-7-14(19)8-6-13/h4-11H,1-3H3 checkY
  • Key:ZWOUXWWGKJBAHQ-UHFFFAOYSA-N checkY
  (verify)

References

edit
  1. ^ Haanaes HR, Benterud UJ, Skoglund LA (November 1986). "RF 46-790 versus paracetamol: effect on post-operative pain". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 24 (11): 598–601. PMID 3491794.
  2. ^ Mohing W, Suckert R, Lataste X (1981). "Comparative study of fluproquazone in the management of post-operative pain". Arzneimittel-Forschung. 31 (5a): 918–20. PMID 6973986.
  3. ^ Wheatley D (May 1982). "Analgesic properties of fluproquazone". Rheumatology and Rehabilitation. 21 (2): 98–100. doi:10.1093/rheumatology/21.2.98. PMID 7043713.
  4. ^ Fankhauser S, Laube W, Marti HR, Schultheiss HR, Vögtlin J, von Graffenried B (1981). "Antipyretic activity of fluproquazone in man". Arzneimittel-Forschung. 31 (5a): 934–5. PMID 6973990.
  5. ^ Lewis JH, Stine JG (2013). "Nonsteroidal Antiinflammatory Drugs and Leukotriene Receptor Antagonists". In Kaplowitz N, DeLeve LD (eds.). Drug-induced Liver Disease (third ed.). Elsevier Inc. ISBN 9780123878175.
  6. ^ Zimmerman HJ (1999). Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Lippincott Williams & Wilkins. ISBN 9780781719520.